View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Chap ter 4.3 Modelling of early viral kinetics and pegylated interferon-alpha-2b pharmacokinetics in patients with HBeAgpositive chronic hepatitis B Martijn J. ter Borg 1 , Bettina E. Hansen 1,2 , Eva Herrmann 3 , Stefan Zeuzem 4 , Yilmaz Cakaloglu 5 , Selim Karayalcin 6 , Robert Flisiak 7 , Annemarie van ‘t Veen 8 , Robert A. de Man 1 , Solko W. Schalm 1 , Harry L.A. Janssen 1 , Bart L. Haagmans 8 for the HBV 99-01 study group Departments of 1 Gastroenterology and Hepatology, 2 Epidemiology and Biostatistics Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands, 3 Faculty of Medicine, Department of Internal Medicine, Saarland University, Homburg/ Saar, Germany, 4 Department of Medicine I, J.W. Goethe-University Hospital, Frankfurt, Germany, 5 Department Gastroenterohepatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey, 6 Department of Gastroenterology, Medical School Cebeci Kampusu, Ankara, Turkey, 7 Department of Infectious Diseases, Medical University of Bialystok, Bialystok, Poland, 8 Department of Virology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands Antiviral Therapy 2007; 12: 1285-1294
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Page 153 and 154:
where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156:
Page 157 and 158:
Page 159 and 160: Discriminant analysis using a MLMM
Page 171 and 172: Appendix Discriminant analysis usin
Page 175: Cha pter 4 Statistical models of ea
Page 178 and 179: Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181: Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183: Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185: Chapter 4.1 182 Figure 1.
Page 186 and 187: Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189: Chapter 4.1 186 suppression in seru
Page 190 and 191: Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194: Cha pter 4.2 Viral dynamics during
Page 195 and 196: INTRODUCTION Viral dynamics during
Page 197 and 198: Viral dynamics during tenofovir the
Page 201 and 202: log HBV DNA (copies/mL) 10.0 9.0 8.
Page 212 and 213: Chapter 4.3 210 ABSTRACT Treatment
Page 214 and 215: Chapter 4.3 212 HBV DNA quantifi ca
Page 216 and 217: Chapter 4.3 214 The resulting model
Page 218 and 219: Chapter 4.3 216 Figure 1. Median HB
Page 220 and 221: Chapter 4.3 218 Table 2: Pharmacoki
Page 222 and 223: Chapter 4.3 220 Figure 3. effects r
Page 224 and 225: Chapter 4.3 222 13-14 This model ta
Page 226 and 227: Chapter 4.3 224 References 1. Kane
Page 228 and 229: Chapter 4.3 226 25. Wolters LM, Han
Page 231: Cha pter 5 Summary and conclusion
Page 234 and 235: Summary and conclusion 232 Therapy
Page 236 and 237: Summary and conclusion 234 who deve
Page 238 and 239: Summary and conclusion 236 fi t mod
Page 241: Cha pter 6 Samenvatting en conclusi
Page 244 and 245: Samenvatting en conclusie 242 posit
Page 246 and 247: Samenvatting en conclusie 244 De ve
Page 248 and 249: Samenvatting en conclusie 246 en na
Page 250: Samenvatting en conclusie 248 In ee
Page 255 and 256: DANKWOORD Dankwoord 253 Met oplucht
Page 257: CUR RICULUM VITAE Curriculum Vitae
Page 260 and 261:
Bibliography 258 Mechanical factors
Page 262 and 263:
Bibliography 260 35. Wolters LM, Ha
Page 264 and 265:
Bibliography 262 Volume Measurement
Page 266 and 267:
Bibliography 264 Quantitative HBV D
Page 268 and 269:
Bibliography 266 to Peginterferon-a
Page 272:
ISBN: 978-90-8559-069-9
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?